CA3218345A1 - Agonistes macrocycliques du recepteur du peptide 1 de type glucagon - Google Patents

Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Download PDF

Info

Publication number
CA3218345A1
CA3218345A1 CA3218345A CA3218345A CA3218345A1 CA 3218345 A1 CA3218345 A1 CA 3218345A1 CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A CA3218345 A CA 3218345A CA 3218345 A1 CA3218345 A1 CA 3218345A1
Authority
CA
Canada
Prior art keywords
preparation
mmol
methyl
title compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218345A
Other languages
English (en)
Inventor
Francisco Javier Agejas Chicharro
Renato Alejandro BAUER
Michael Gregory Bell
Qi Chen
Graham Robert Cumming
Todd Fields
Douglas Linn Gernert
Joseph Daniel HO
Talbi Abelkader KAOUDI
Thierry Jean MASQUELIN
Jose Miguel Minguez Ortega
Julian PRIEGO SOLER
Antonio Rodriguez Hergueta
Eric Michael Woerly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3218345A1 publication Critical patent/CA3218345A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dans un mode de réalisation, la présente invention concerne un composé de formule : ou un sel pharmaceutiquement acceptable de celui-ci, et des méthodes d'utilisation de ce composé pour le traitement du diabète sucré de type II.
CA3218345A 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon Pending CA3218345A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163191034P 2021-05-20 2021-05-20
US63/191,034 2021-05-20
US202163254564P 2021-10-12 2021-10-12
US63/254,564 2021-10-12
EP21383172 2021-12-21
EP21383172.0 2021-12-21
PCT/US2022/029958 WO2022246019A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du récepteur du peptide 1 de type glucagon

Publications (1)

Publication Number Publication Date
CA3218345A1 true CA3218345A1 (fr) 2022-11-24

Family

ID=82016585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218345A Pending CA3218345A1 (fr) 2021-05-20 2022-05-19 Agonistes macrocycliques du recepteur du peptide 1 de type glucagon

Country Status (10)

Country Link
EP (1) EP4341255A1 (fr)
JP (1) JP7703691B2 (fr)
KR (1) KR20230173166A (fr)
AU (1) AU2022275931B2 (fr)
BR (1) BR112023022851A2 (fr)
CA (1) CA3218345A1 (fr)
IL (1) IL308397A (fr)
MX (1) MX2023013717A (fr)
TW (1) TWI843104B (fr)
WO (1) WO2022246019A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
US20260097037A1 (en) 2022-09-22 2026-04-09 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
WO2024102625A1 (fr) * 2022-11-11 2024-05-16 Eli Lilly And Company Agonistes de récepteur du peptide 1 de type glucagon
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (fr) 2024-01-24 2025-07-31 Pfizer Inc. Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids
CN119219759B (zh) * 2024-10-22 2026-03-27 浙江工业大学 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3555064B9 (fr) 2016-12-16 2023-03-01 Pfizer Inc. Agonistes du récepteur glp-1 et leurs utilisations
CA3045644C (fr) 2018-06-13 2024-01-16 Pfizer Inc. Antagonistes du recepteur glp-1 et leurs utilisations
ES2943510T3 (es) 2018-06-15 2023-06-13 Pfizer Agonistas del receptor GLP-1 y usos del mismo
CR20210341A (es) 2018-11-22 2021-11-25 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (fr) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
CA3157525A1 (fr) * 2019-10-25 2021-04-29 Gilead Sciences, Inc. Composes modulateurs de glp-1r
JP7386997B2 (ja) 2019-11-15 2023-11-27 イルドン ファーマシューティカル カンパニー リミテッド Ｇｌｐ－１受容体アゴニストおよびその使用
KR20210069000A (ko) 2019-12-02 2021-06-10 현대약품 주식회사 Glp-1 수용체 작용제
WO2021154796A1 (fr) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Composés modulateurs de glp-1r
WO2021160127A1 (fr) 2020-02-13 2021-08-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
MY207021A (en) 2020-03-18 2025-01-24 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
FI4143183T3 (fi) 2020-04-29 2026-01-07 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
PH12022553313A1 (en) 2020-06-04 2023-04-12 Hangzhou Sciwind Biosciences Co Ltd Five-membered heteroaromatic imidazole compound and use thereof
US20230234968A1 (en) 2020-06-10 2023-07-27 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
WO2021254470A1 (fr) 2020-06-19 2021-12-23 江苏恒瑞医药股份有限公司 Dérivé de 6-oxo-3,6-dihydropyridine, son procédé de préparation et son utilisation en médecine
WO2021259309A1 (fr) 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Agoniste du récepteur glp-1, composition pharmaceutique et utilisation associées
TW202214622A (zh) 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
PE20231206A1 (es) 2020-08-21 2023-08-17 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
WO2022042691A1 (fr) 2020-08-28 2022-03-03 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
AU2021306414B2 (en) 2020-09-01 2026-01-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
WO2022068772A1 (fr) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale
EP4227299A4 (fr) 2020-10-12 2025-04-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
JP2023546054A (ja) 2020-10-13 2023-11-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
EP4229050A4 (fr) 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用

Also Published As

Publication number Publication date
JP7703691B2 (ja) 2025-07-07
WO2022246019A1 (fr) 2022-11-24
TW202310838A (zh) 2023-03-16
IL308397A (en) 2024-01-01
EP4341255A1 (fr) 2024-03-27
JP2024521073A (ja) 2024-05-28
KR20230173166A (ko) 2023-12-26
AU2022275931A1 (en) 2023-11-02
AU2022275931B2 (en) 2024-08-15
TWI843104B (zh) 2024-05-21
MX2023013717A (es) 2024-01-16
BR112023022851A2 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
CA3218345A1 (fr) Agonistes macrocycliques du recepteur du peptide 1 de type glucagon
CA3144055C (fr) Agonistes du recepteur du peptide de type glucagon 1
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
EP2038272B1 (fr) Inhibiteurs de pyridinonyle pdk1
CN102665718B (zh) 可用作pdk1抑制剂的杂环化合物
US10017502B2 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
JP2017001991A (ja) 新規ベンズオキサゾロン化合物
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
TWI843949B (zh) 黑皮質素4(melanocortin 4)受體拮抗劑及其用途
JP2025537254A (ja) グルカゴン様ペプチド１受容体アゴニスト
KR20250085816A (ko) 글루카곤-유사 펩티드 1 수용체 효능제
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CA2828518C (fr) Derives de pyridynyl- et pyrasinyl-methyloxy-aryl utiles comme inhibiteurs de tyrosine kinase spleniqueyk)
EP3807273B1 (fr) Dérivés d'azaindole comme inhibiteurs de la kinase rho
RU2662157C2 (ru) 2-пиридоновое соединение
US20240343740A1 (en) Macrocyclic glucagon-like peptide 1 receptor agonists
CN117355517A (zh) 大环胰高血糖素样肽1受体激动剂
WO2025264700A1 (fr) Composés agonistes du récepteur gip
CA3288258A1 (fr) Nouvel inhibiteur de b0at1
WO2026030603A1 (fr) Composés agonistes du récepteur gip
WO2026026956A1 (fr) Composé inhibiteur de tacc, composition pharmaceutique, son procédé de préparation et son utilisation
EA048136B1 (ru) Спиросоединения в качестве антагонистов рецептора меланокортина 4 и их применения
HK1207856B (en) 2-pyridone compound
KR20110109917A (ko) 신규한 퀴녹살린 유도체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231107

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250507

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250507